Search
Balsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approved[F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnIn August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalOn September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.
Tramadol
go.drugbank.com/drugs/DB00193ApprovedInvestigationalTramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of actio...
Mixtures: Nra-tramadol/acetXP12B
go.drugbank.com/drugs/DB04928InvestigationalIt was granted Fast Track status for this indication by the FDA in November 2004.
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalIt was granted FDA orphan designation in November 2018.[L47067]
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA
Synonyms: Bei Fa Zhu Dankang